Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Curcumin liposomal - Signpath Pharma

Drug Profile

Curcumin liposomal - Signpath Pharma

Alternative Names: Diferuloylmethane; Lipocurc; Lipocurcumin; Liposomal curcumin

Latest Information Update: 20 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Signpath Pharma
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Solid tumours

Most Recent Events

  • 01 Mar 2023 Phase-I/II clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Late-stage disease) in USA (IV) (NCT05768919)
  • 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Recurrent) in Austria (IV, Infusion)
  • 31 Oct 2019 SignPath Pharma intends to conduct further clinical trials of liposomal curcumin, in 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top